WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous close | 14.560 |
| Open | 14.880 |
| Bid | 13.700 x 0 |
| Ask | 13.720 x 0 |
| Day's range | 13.520 - 14.920 |
| 52-week range | 12.420 - 52.450 |
| Volume | |
| Avg. volume | 57,743,512 |
| Market cap | 57.112B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 16.53 |
| EPS (TTM) | 0.830 |
| Earnings date | 26 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.63 |
PR NewswireWuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today published its 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's substantial progress in advancing sustainable development.
Yahoo FinanceAstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
PR NewswireWuXi Biologics Reports Solid 2023 Annual Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
